Menu

Abattis Announces Successful Closing of Pro Natura Acquisition

May 21, 2019    |    Abattis Bioceuticals

VANCOUVER, BRITISH COLUMBIA / May 21st, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”).

Company Newsletter

Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure,  and provide cannabis industry highlights as they pertain to the Company. The first issue of the Newsletter will also provide answers to various Frequently Asked Questions (“FAQs”) we have recently received from our stakeholders. To receive the Newsletter, investors and stakeholders are encouraged to sign up at www.abattis.com/newsletter.

About Abattis Bioceuticals Corp.

Abattis is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company. In addition to the Company’s flagship cultivation asset located on British Columbia’s Gabriola Island, Abattis is aggressively building its portfolio of assets including through the acquisition of 140 genetic strains and a robust portfolio of fertilizers and nutrients, custom formulated for the emerging cannabis market.

Abattis’ products and services divisions include its Abattis-branded vaporizer line, as well as the proprietary cannabinoid therapeutic, COMFORT™, formulated to treat chronic pain and inflammation. Abattis continues to service the cultivation industry through its service agreements with licensed laboratory Northern Vine Canada Inc., and Dicentra Inc., one of Canada’s largest regulatory advisory firms.

Abattis continues to pioneer cutting-edge research in partnership with the University of British Columbia and Mitacs, to research and develop nanoemulsified cannabinoid-rich hemp oil and cannabinoid-infused products. Abattis has also solidified key investments into XLABS Therapeutics (ONT) Inc., building one of Canada’s largest cannabinoid manufacturing labs, as well as blockchain service and cryptocurrency platforms focused solely on cannabis product and service transactions.

ON BEHALF OF THE BOARD, ABATTIS BIOCEUTICALS CORP,
“Rob Abenante”
Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com

For inquiries please contact (808) 650-3007 or at investors@abattis.com.  Abattis IR is managed by Canada One Communications Inc.

About Canada One Communications Inc.

Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “promising”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include, statements regarding: (i) the restoration of market confidence in the Company following the BCSC not extending the Order against Abattis; (ii) the Company becoming a fully-integrated medicinal marijuana company; and (iii) that the Company will be able to generate increased shareholder value. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on these forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties including: that the Order issued by the BCSC will have an ongoing negative material effect on the Company; that the Company will not be well capitalized; that the Company or the Company’s wholly-owned subsidiary, Gabriola Green Farms, will not receive the necessary regulatory approvals for its current or future products and operations; that the Company will not see revenue growth at all or as anticipated; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s filings available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.